Mesenchymal-epithelial transition in lymph node metastases of oral squamous cell carcinoma is accompanied by ZEB1 expression.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
19 04 2023
Historique:
received: 27 10 2022
accepted: 01 04 2023
medline: 21 4 2023
pubmed: 20 4 2023
entrez: 19 04 2023
Statut: epublish

Résumé

Oral squamous cell carcinoma (OSCC), an HPV-negative head and neck cancer, frequently metastasizes to the regional lymph nodes but only occasionally beyond. Initial phases of metastasis are associated with an epithelial-mesenchymal transition (EMT), while the consolidation phase is associated with mesenchymal-epithelial transition (MET). This dynamic is referred to as epithelial-mesenchymal plasticity (EMP). While it is known that EMP is essential for cancer cell invasion and metastatic spread, less is known about the heterogeneity of EMP states and even less about the heterogeneity between primary and metastatic lesions. To assess both the heterogeneity of EMP states in OSCC cells and their effects on stromal cells, we performed single-cell RNA sequencing (scRNAseq) of 5 primary tumors, 9 matching metastatic and 5 tumor-free lymph nodes and re-analyzed publicly available scRNAseq data of 9 additional primary tumors. For examining the cell type composition, we performed bulk transcriptome sequencing. Protein expression of selected genes were confirmed by immunohistochemistry. From the 23 OSCC lesions, the single cell transcriptomes of a total of 7263 carcinoma cells were available for in-depth analyses. We initially focused on one lesion to avoid confounding inter-patient heterogeneity and identified OSCC cells expressing genes characteristic of different epithelial and partial EMT stages. RNA velocity and the increase in inferred copy number variations indicated a progressive trajectory towards epithelial differentiation in this metastatic lesion, i.e., cells likely underwent MET. Extension to all samples revealed a less stringent but essentially similar pattern. Interestingly, MET cells show increased activity of the EMT-activator ZEB1. Immunohistochemistry confirmed that ZEB1 was co-expressed with the epithelial marker cornifin B in individual tumor cells. The lack of E-cadherin mRNA expression suggests this is a partial MET. Within the tumor microenvironment we found immunomodulating fibroblasts that were maintained in primary and metastatic OSCC. This study reveals that EMP enables different partial EMT and epithelial phenotypes of OSCC cells, which are endowed with capabilities essential for the different stages of the metastatic process, including maintenance of cellular integrity. During MET, ZEB1 appears to be functionally active, indicating a more complex role of ZEB1 than mere induction of EMT.

Sections du résumé

BACKGROUND
Oral squamous cell carcinoma (OSCC), an HPV-negative head and neck cancer, frequently metastasizes to the regional lymph nodes but only occasionally beyond. Initial phases of metastasis are associated with an epithelial-mesenchymal transition (EMT), while the consolidation phase is associated with mesenchymal-epithelial transition (MET). This dynamic is referred to as epithelial-mesenchymal plasticity (EMP). While it is known that EMP is essential for cancer cell invasion and metastatic spread, less is known about the heterogeneity of EMP states and even less about the heterogeneity between primary and metastatic lesions.
METHODS
To assess both the heterogeneity of EMP states in OSCC cells and their effects on stromal cells, we performed single-cell RNA sequencing (scRNAseq) of 5 primary tumors, 9 matching metastatic and 5 tumor-free lymph nodes and re-analyzed publicly available scRNAseq data of 9 additional primary tumors. For examining the cell type composition, we performed bulk transcriptome sequencing. Protein expression of selected genes were confirmed by immunohistochemistry.
RESULTS
From the 23 OSCC lesions, the single cell transcriptomes of a total of 7263 carcinoma cells were available for in-depth analyses. We initially focused on one lesion to avoid confounding inter-patient heterogeneity and identified OSCC cells expressing genes characteristic of different epithelial and partial EMT stages. RNA velocity and the increase in inferred copy number variations indicated a progressive trajectory towards epithelial differentiation in this metastatic lesion, i.e., cells likely underwent MET. Extension to all samples revealed a less stringent but essentially similar pattern. Interestingly, MET cells show increased activity of the EMT-activator ZEB1. Immunohistochemistry confirmed that ZEB1 was co-expressed with the epithelial marker cornifin B in individual tumor cells. The lack of E-cadherin mRNA expression suggests this is a partial MET. Within the tumor microenvironment we found immunomodulating fibroblasts that were maintained in primary and metastatic OSCC.
CONCLUSIONS
This study reveals that EMP enables different partial EMT and epithelial phenotypes of OSCC cells, which are endowed with capabilities essential for the different stages of the metastatic process, including maintenance of cellular integrity. During MET, ZEB1 appears to be functionally active, indicating a more complex role of ZEB1 than mere induction of EMT.

Identifiants

pubmed: 37076857
doi: 10.1186/s12967-023-04102-w
pii: 10.1186/s12967-023-04102-w
pmc: PMC10114373
doi:

Substances chimiques

Cadherins 0
ZEB1 protein, human 0
Zinc Finger E-box-Binding Homeobox 1 0

Banques de données

figshare
['10.6084/m9.figshare.20905837.v1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

267

Informations de copyright

© 2023. The Author(s).

Références

Cell Rep. 2021 Apr 13;35(2):108990
pubmed: 33852841
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Genet. 2019 Sep;51(9):1389-1398
pubmed: 31477929
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
Mol Syst Biol. 2019 Jun 19;15(6):e8746
pubmed: 31217225
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Dev Cell. 2019 May 6;49(3):313-316
pubmed: 31063750
BMC Genomics. 2018 Jun 19;19(1):477
pubmed: 29914354
J Invest Dermatol. 2017 May;137(5):e101-e104
pubmed: 28411839
Oncogene. 2015 Aug 20;34(34):4531-44
pubmed: 25486435
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Dev Cell. 2019 May 6;49(3):332-346
pubmed: 31063753
Gene. 2020 May 30;741:144552
pubmed: 32165297
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
Oncogene. 2010 Jun 17;29(24):3490-500
pubmed: 20418909
Clin Cancer Res. 2020 May 1;26(9):2257-2267
pubmed: 31932494
Immunity. 2018 May 15;48(5):1014-1028.e6
pubmed: 29752062
Oncogene. 2021 Aug;40(32):5049-5065
pubmed: 34239045
EMBO J. 2021 Sep 15;40(18):e108647
pubmed: 34459003
Nat Commun. 2019 Dec 6;10(1):5587
pubmed: 31811131
Commun Biol. 2020 Apr 23;3(1):188
pubmed: 32327715
Nat Genet. 2016 Aug;48(8):838-47
pubmed: 27322546
Nat Cell Biol. 2014 Sep;16(9):864-75
pubmed: 25086746
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683
pubmed: 31189965
Clin Cancer Res. 2021 May 1;27(9):2636-2647
pubmed: 33622705
Tumour Biol. 2013 Feb;34(1):65-70
pubmed: 22976543
Cell Rep. 2015 Dec 22;13(11):2456-2469
pubmed: 26670048
Mol Cell. 2017 Jun 15;66(6):772-779
pubmed: 28622522
Cancer Res. 2014 Jun 1;74(11):2999-3010
pubmed: 24710408
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Nat Immunol. 2007 Nov;8(11):1255-65
pubmed: 17893676
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Nat Commun. 2021 Dec 17;12(1):7338
pubmed: 34921143
Oncotarget. 2016 May 10;7(19):27067-84
pubmed: 27008704
Cell Death Differ. 2002 May;9(5):486-92
pubmed: 11973607
Int Immunopharmacol. 2021 Aug;97:107681
pubmed: 33932697
J Exp Med. 2001 Sep 17;194(6):855-61
pubmed: 11561000
Sci Rep. 2021 May 17;11(1):10433
pubmed: 34001952
Cancer Sci. 2009 Nov;100(11):2202-9
pubmed: 19673887
Genome Res. 2019 Aug;29(8):1363-1375
pubmed: 31340985
Nat Methods. 2014 Jul;11(7):740-2
pubmed: 24836921
Cell. 2020 Jul 23;182(2):497-514.e22
pubmed: 32579974
Cancer Res. 2004 Nov 15;64(22):8262-70
pubmed: 15548693
Nat Rev Cancer. 2019 Dec;19(12):716-732
pubmed: 31666716
Invest Ophthalmol Vis Sci. 2010 May;51(5):2466-75
pubmed: 20042643
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Dev Cell. 2018 Jun 18;45(6):681-695.e4
pubmed: 29920274
EMBO Rep. 2008 Jun;9(6):582-9
pubmed: 18483486
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Nat Genet. 2020 Nov;52(11):1208-1218
pubmed: 33128048
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Int J Cancer. 2003 Mar 1;103(6):768-74
pubmed: 12516096
Br J Cancer. 2021 Jan;124(1):259-269
pubmed: 33299129
Cancer Cell. 2012 Dec 11;22(6):725-36
pubmed: 23201165
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94
pubmed: 19812304
Carcinogenesis. 2022 Oct 22;43(9):851-864
pubmed: 35974187
Nat Commun. 2019 Aug 21;10(1):3763
pubmed: 31434891
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Sci Adv. 2021 Jul 28;7(31):
pubmed: 34321199
Cell Rep. 2019 Feb 5;26(6):1627-1640.e7
pubmed: 30726743
Cell Metab. 2011 Sep 7;14(3):285-6
pubmed: 21907134
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Nat Commun. 2020 May 1;11(1):2142
pubmed: 32358524
J Immunol. 2015 Feb 15;194(4):1389-94
pubmed: 25663676
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Nat Cell Biol. 2019 Jan;21(1):102-112
pubmed: 30602760
Clin Cancer Res. 2017 Aug 15;23(16):4651-4661
pubmed: 28490464
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40
pubmed: 9465086
Sci Rep. 2022 Nov 27;12(1):20404
pubmed: 36437265
Genome Biol. 2020 Feb 12;21(1):36
pubmed: 32051003

Auteurs

Kai Horny (K)

Translational Skin Cancer Research, German Cancer Consortium (DKTK), 45141, Essen, Germany.
German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

Christoph Sproll (C)

Department of Oral- and Maxillofacial Surgery, Medical Faculty, University Hospital of the Heinrich-Heine-University, Düsseldorf, Germany.

Lukas Peiffer (L)

Translational Skin Cancer Research, German Cancer Consortium (DKTK), 45141, Essen, Germany.
German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

Frauke Furtmann (F)

Translational Skin Cancer Research, German Cancer Consortium (DKTK), 45141, Essen, Germany.
German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Department of Dermatology, University Medicine Essen, 45141, Essen, Germany.

Patricia Gerhardt (P)

Translational Skin Cancer Research, German Cancer Consortium (DKTK), 45141, Essen, Germany.
German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

Jan Gravemeyer (J)

Translational Skin Cancer Research, German Cancer Consortium (DKTK), 45141, Essen, Germany.
German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

Nikolas H Stoecklein (NH)

Department of General, Visceral and Pediatric Surgery, Medical Faculty, University Hospital of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

Ivelina Spassova (I)

Translational Skin Cancer Research, German Cancer Consortium (DKTK), 45141, Essen, Germany.
German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Department of Dermatology, University Medicine Essen, 45141, Essen, Germany.

Jürgen C Becker (JC)

Translational Skin Cancer Research, German Cancer Consortium (DKTK), 45141, Essen, Germany. j.becker@dkfz.de.
German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. j.becker@dkfz.de.
Department of Dermatology, University Medicine Essen, 45141, Essen, Germany. j.becker@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH